Whitepapers

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Resource Types

Pharma supply chains: From fragile to agile
Introduction The pharmaceutical supply chain is undergoing a major transformation, shifting from fragile to agile models to enhance resilience. The COVID-19 pandemic exposed vulnerabilities in...
Read
Read
CMOs bask in pill promise
Introduction Contract manufacturing organizations (CMOs) are witnessing increased demand for outsourcing oral solid dosage (OSD), particularly from Europe. The global OSD contract manufacturing market, valued...
Read
Read
ADCs-Biological missiles for targeted therapies
Introduction The concept of targeted cytotoxic drug delivery to reduce systemic toxicity while increasing treatment efficacy was first introduced by Paul Ehrlich in 1913. However,...
Read
Read
Pharma 4.0-Taking CDMOs factory by storm
Introduction Contract manufacturing firms are ramping up the adoption of Pharma 4.0 technologies as regulators and customers increasingly look for transparency and integrity in manufacturing...
Read
Read
Net zero pledge: CDMOs go greener
Introduction According to industry reports, the pharmaceutical sector accounts for as much as 4.4% of emissions worldwide, and if no action is taken, its greenhouse...
Read
Read
New modalities hog the limelight
Introduction The biopharmaceutical industry is experiencing a paradigm shift as advanced therapies such as mRNA-based drugs, cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), and...
Read
Read
Integrated outsourcing for drug development
Introduction This article explores the pros and cons of integrated versus standalone outsourcing services based on an industry-wide survey conducted by Pharma Intelligence in partnership...
Read
Read
pDNA-Cracking the Code
Introduction pDNA is critical to many advanced and emerging therapies, including cell and gene therapies and mRNA vaccines, as it is the key starting material...
Read
Read
How to overcome solubility challenges by applying amorphous solid dispersion
Introduction Poor solubility is among the primary causes of low bioavailability for orally administered drugs. Because over 85% of pharmaceuticals are administered orally, improving solubility...
Read
Read
Harnessing artificial intelligence and digital technologies across the biopharma value chain
Introduction Artificial intelligence (AI) has the potential to revolutionize drug development through improved efficiency, accuracy, and speed. However, research indicates that biopharma companies have been...
Read
Read

To view or email, Please share your details view

Download PDF
Download PDF

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details